Skip to Content
Regeneron Pharmaceuticals Inc. Logo.

Press Releases

September 24, 2026 4:05 PM EDT

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

Read press release : Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

August 19, 2026 4:05 PM EDT

Regeneron Announces Investor Conference Presentations

Read press release : Regeneron Announces Investor Conference Presentations

August 19, 2026 1:58 PM EDT

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Read press release : Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

July 31, 2026 7:00 AM EDT

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Read press release : Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

July 30, 2026 6:30 AM EDT

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Read press release : Regeneron Reports Second Quarter 2026 Financial and Operating Results

June 25, 2026 4:05 PM EDT

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Read press release : Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

June 22, 2026 7:00 AM EDT

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Read press release : Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

June 4, 2026 7:00 AM EDT

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Read press release : Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

May 28, 2026 4:00 PM EDT

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Read press release : Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

May 22, 2026 7:00 AM EDT

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

Read press release : Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Back to top